var data={"title":"Dasatinib: Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Dasatinib: Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/228674?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=dasatinib-patient-drug-information\" class=\"drug drug_patient\">see &quot;Dasatinib: Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F3020472\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Sprycel</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F4663157\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Sprycel</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F3020476\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Antineoplastic Agent, BCR-ABL Tyrosine Kinase Inhibitor;</li>\n      <li>\n        Antineoplastic Agent, Tyrosine Kinase Inhibitor</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F3020532\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> The effect of discontinuation on long-term disease outcome after achieving cytogenetic response (including complete cytogenetic response) or major molecular response is not known.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Chronic myelogenous leukemia (CML), Philadelphia chromosome-positive (Ph+), newly diagnosed in chronic phase: </b> Oral: 100 mg once daily until disease progression or unacceptable toxicity. In clinical studies, a dose escalation to 140 mg once daily was allowed in patients not achieving hematologic or cytogenetic response at recommended initial dosage.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>CML, Ph+, resistant or intolerant:</b> Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Chronic phase:</i> 100 mg once daily until disease progression or unacceptable toxicity. In clinical studies, a dose escalation to 140 mg once daily was allowed in patients not achieving hematologic or cytogenetic response at recommended initial dosage.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Accelerated or blast phase:</i> 140 mg once daily until disease progression or unacceptable toxicity. In clinical studies, a dose escalation to 180 mg once daily was allowed in patients not achieving hematologic or cytogenetic response at recommended initial dosage.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Acute lymphoblastic leukemia (ALL), Ph+: </b> Oral: 140 mg once daily until disease progression or unacceptable toxicity. In clinical studies, a dose escalation to 180 mg once daily was allowed in patients not achieving hematologic or cytogenetic response at recommended initial dosage.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Gastrointestinal stromal tumors (GIST; off-label use): </b> Oral: 70 mg twice daily (Montemurro 2012; Trent 2011).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Missed doses:</i> If a dose is missed, take the next regularly scheduled dose; 2 doses should not be taken at the same time.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>Dosage adjustment for concomitant strong CYP3A4 inhibitors:</b> Avoid concomitant administration with strong CYP3A4 inhibitors and grapefruit juice; if concomitant administration with a strong CYP3A4 inhibitor cannot be avoided, consider reducing dasatinib from 140 mg once daily to 40 mg once daily <b>or</b> from 100 mg once daily to 20 mg once daily <b>or</b> from 70 mg once daily to 20 mg once daily, with careful monitoring. If taking dasatinib 60 mg or 40 mg once daily, withhold dasatinib until the strong CYP3A4 inhibitor is discontinued; allow a washout period (~1 week) prior to reinitiating dasatinib. If reduced dose is not tolerated, the strong CYP3A4 inhibitor must be discontinued or dasatinib therapy temporarily held until concomitant inhibitor use has ceased. When a strong CYP3A4 inhibitor is discontinued, allow a washout period (~1 week) prior to adjusting dasatinib dose upward.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosage adjustment for concomitant strong CYP3A4 inducers:</b> Avoid concomitant administration with strong CYP3A4 inducers and St John&rsquo;s wort; if concomitant administration with a strong CYP3A4 inducer cannot be avoided, consider increasing the dasatinib dose with careful monitoring.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50836850\" class=\"block dop drugH1Div\"><span class=\"drugH1\">Dosing: Pediatric</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> The effect of discontinuation on long-term disease outcome after achieving cytogenetic response (including complete cytogenetic response) or major molecular response is not known.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Chronic myelogenous leukemia (CML), Philadelphia chromosome-positive (Ph+), chronic phase:</b> Oral: Children &ge;1 year and Adolescents: <b>Note:</b> Tablet dosing is not recommended for patients &lt;10 kg. Continue dasatinib until disease progression or unacceptable toxicity. Recalculate the dose every 3 months or as clinically necessary based on changes in body weight.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>10 to &lt;20 kg:</i> 40 mg once daily; may escalate to 50 mg once daily if hematologic or cytogenetic response is not achieved</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>20 to &lt;30 kg:</i> 60 mg once daily; may escalate to 70 mg once daily if hematologic or cytogenetic response is not achieved</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>30 to &lt;45 kg:</i> 70 mg once daily; may escalate to 90 mg once daily if hematologic or cytogenetic response is not achieved</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>&ge;45 kg:</i> 100 mg once daily; may escalate to 120 mg once daily if hematologic or cytogenetic response is not achieved</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosage adjustment for concomitant strong CYP3A4 inhibitors or inducers:</b> Refer to Adult dosing: Dosage adjustment for concomitant strong CYP3A4 inhibitors <b>or</b> dosage adjustment for concomitant strong CYP3A4 inducers.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F3020533\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F15121210\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer&rsquo;s labeling. However, &lt;4% of dasatinib and metabolites are renally excreted.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F7882679\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">No initial dosage adjustment is necessary; use with caution. Transaminase or bilirubin elevations during treatment may be managed with treatment interruption or dose reduction.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F3020534\" class=\"block dot drugH1Div\"><span class=\"drugH1\">Dosing: Adjustment for Toxicity</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Hematologic toxicity:</b> <b>Note:</b> Growth factor support may be considered in patients with resistant myelosuppression.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Adults:</i></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Chronic phase CML</i> (100 mg daily starting dose): For ANC &lt;500/mm<sup>3</sup> or platelets &lt;50,000/mm<sup>3</sup>, withhold treatment until ANC &ge;1000/mm<sup>3</sup> and platelets &ge;50,000/mm<sup>3</sup>; then resume treatment at the original starting dose if recovery occurs in &le;7 days. If platelets &lt;25,000/mm<sup>3</sup> or recurrence of ANC &lt;500/mm<sup>3</sup> for &gt;7 days, withhold treatment until ANC &ge;1000/mm<sup>3</sup> and platelets &ge;50,000/mm<sup>3</sup>; then resume treatment at 80 mg once daily (second episode). For third episode, further reduce dose to 50 mg once daily (for newly diagnosed patients) or discontinue (for patients resistant or intolerant to prior therapy)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Accelerated or blast phase CML and Ph+ ALL</i> (140 mg once daily starting dose): For ANC &lt;500/mm<sup>3</sup> or platelets &lt;10,000/mm<sup>3</sup>, if cytopenia unrelated to leukemia, withhold treatment until ANC &ge;1,000/mm<sup>3</sup> and platelets &ge;20,000/mm<sup>3</sup>; then resume treatment at the original starting dose. If cytopenia recurs, withhold treatment until ANC &ge;1,000/mm<sup>3</sup> and platelets &ge;20,000/mm<sup>3</sup>; then resume treatment at 100 mg once daily (second episode) or 80 mg once daily (third episode). For cytopenias related to leukemia (confirm with marrow aspirate or biopsy), consider dose escalation to 180 mg once daily.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Pediatrics: </i></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">If cytopenia (eg, neutropenia or thrombocytopenia) persists for &gt;3 weeks, determine if cytopenia is due to leukemia by performing a marrow aspirate or biopsy.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">If cytopenia is unrelated to leukemia, withhold dasatinib until ANC &ge;1,000/mm<sup>3</sup> and platelets &ge;75,000/mm<sup>3</sup> and resume dasatinib at the original starting dose or at a reduced dose.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">If cytopenia recurs, repeat marrow aspirate/biopsy and resume dasatinib at a reduced dose.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <b>Note: </b>If &ge;grade 3 neutropenia or thrombocytopenia recurs during complete hematologic response, interrupt dasatinib therapy and resume at a reduced dose. Temporary dose reductions for intermediate degrees of cytopenia and disease response may be used as needed.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <b>\n        <i>Recommended dose reductions for neutropenia and thrombocytopenia:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">If the original starting dose is 40 mg daily, may reduce dose to 20 mg once daily (one-level dose reduction); further dose reductions cannot be made due to available tablet sizes</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">If the original starting dose is 60 mg once daily, may reduce dose to 40 mg once daily (one-level dose reduction), and then to 20 mg once daily (two-level dose reduction)</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">If the original starting dose is 70 mg once daily, may reduce dose to 60 mg once daily (one-level dose reduction), and then to 50 mg once daily (two-level dose reduction)</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">If the original starting dose is 100 mg once daily, may reduce dose to 80 mg once daily (one-level dose reduction), and then to 70 mg once daily (two-level dose reduction)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Nonhematologic toxicity:</b> Withhold treatment until toxicity improvement or resolution; if appropriate, resume treatment at a reduced dose based on the event severity and recurrence.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Dermatologic toxicities</i>: Manage rash with antihistamines or topical or systemic steroids (Khoury 2009), or treatment interruption, dose reduction, or discontinuation. Discontinue if dasatinib-related severe mucocutaneous reaction occurs.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Fluid retention:</i> Manage with diuretics, short courses of corticosteroids, and/or supportive care. Severe pleural effusions may require thoracentesis and oxygen therapy; consider dose reduction or treatment interruption. For grade 3 pleural effusion, withhold treatment until resolves to grade 1 or lower and consider corticosteroids (eg, prednisone 20 to 40 mg/day for 3 to 4 days), diuretics, thoracentesis and/or pleurodesis; may resume dasatinib at a decreased dose when effusion resolves (Khoury 2009).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Pulmonary arterial hypertension:</i> Discontinue with confirmed pulmonary arterial hypertension.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F3020543\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Sprycel: 20 mg, 50 mg, 70 mg, 80 mg, 100 mg, 140 mg</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F3020474\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">No</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F3020536\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">Administer once daily (morning or evening). May be taken without regard to food. Swallow whole; do not break, cut, crush, or chew tablets. Take with a meal if GI upset occurs (Khoury 2009). Do not administer proton pump inhibitors and H<sub>2</sub> blockers concomitantly with dasatinib. If needed, may consider antacid administration, separated by at least 2 hours before or 2 hours after the dasatinib dose.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F49130978\" class=\"block hazard drugH1Div\"><span class=\"drugH1\">Hazardous Drugs Handling Considerations</span>\n    <p style=\"text-indent:0em;\">Hazardous agent (NIOSH 2016 [group 1]). </p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Use appropriate precautions for receiving, handling, administration, and disposal. Gloves (single) should be worn during receiving, unpacking, and placing in storage.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">NIOSH recommends single gloving for administration of intact tablets or capsules. If manipulating tablets/capsules (eg, to prepare an oral suspension), NIOSH recommends double gloving, a protective gown, and preparation in a controlled device; if not prepared in a controlled device, respiratory and eye/face protection as well as ventilated engineering controls are recommended. NIOSH recommends double gloving, a protective gown, and (if there is a potential for vomit or spit up) eye/face protection for administration of an oral liquid/feeding tube administration (NIOSH 2016).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F3020479\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Acute lymphoblastic leukemia:</b> Treatment of Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL) in adult patients with resistance or intolerance to prior therapy.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Chronic myeloid leukemia:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Adults: Treatment of newly diagnosed Ph+ chronic myeloid leukemia (CML) in chronic phase; treatment of chronic, accelerated, or myeloid or lymphoid blast phase Ph+ CML with resistance or intolerance to prior therapy, including imatinib.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Pediatrics: Treatment of Ph+ CML in chronic phase.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25475178\" class=\"block off-label drugH1Div\"><span class=\"drugH1\">Use: Off-Label</span>\n    <p>Gastrointestinal stromal tumor (GIST)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F3401602\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues: </span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Dasatinib may be confused with bosutinib, dabrafenib, imatinib, nilotinib, PONATinib, SUNItinib, vandetanib</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">High alert medication:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">This medication is in a class the Institute for Safe Medication Practices (ISMP) includes among its list of drug classes which have a heightened risk of causing significant patient harm when used in error.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F3020507\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse reactions occurred in adults unless otherwise indicated.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&ge;10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Cardiovascular: Facial edema, peripheral edema</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Headache (adults and children: 12% to 33%), fatigue (adults: 8% to 26%; children: 10%), pain (11%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Dermatologic: Skin rash (adults and children: 11% to 21%), pruritus (12%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Endocrine &amp; metabolic: Fluid retention (adults: 19% to 48%; grades 3/4: 1% to 8%; cardiac-related: 9%; children, grades 1 or 2: 10%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Diarrhea (adults: 17% to 31%; children: 21%), nausea (adults and children: 8% to 24%), vomiting (adults and children: 5% to 16%), abdominal pain (adults and children: 7% to 16%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hematologic &amp; oncologic: Thrombocytopenia (grades 3/4: 22% to 85%), neutropenia (grades 3/4: 29% to 79%), anemia (grades 3/4: 13% to 74%), hemorrhage (8% to 26%; grades 3/4: 1% to 9%), febrile neutropenia (4% to 12%; grades 3/4: 4% to 12%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Infection: Infection (9% to 14%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Local: Localized edema (3% to 22%; superficial)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Neuromuscular &amp; skeletal: Musculoskeletal pain (&lt;22%), limb pain (children: 19%), myalgia (7% to 13%), arthralgia (adults and children: &le;13%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Respiratory: Pleural effusion (5% to 28%; grades 3/4: &le;7%), dyspnea (3% to 24%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Miscellaneous: Fever (6% to 18%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">1% to &lt;10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Cardiovascular: Cardiac conduction disturbance (7%), ischemic heart disease (4%), cardiac disease (&le;4%), edema (&le;4%; generalized), pericardial effusion (&le;4%; grades 3/4: &le;1%), prolonged Q-T interval on ECG (&le;1%), cardiac arrhythmia, chest pain, flushing, hypertension, palpitations, tachycardia</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Intracranial hemorrhage (&le;3%; grades 3/4: &le;3%), chills, depression, dizziness, drowsiness, insomnia, myasthenia, neuropathy, peripheral neuropathy</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Dermatologic: Acne vulgaris, alopecia, dermatitis, eczema, hyperhidrosis, urticaria, xeroderma</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Endocrine &amp; metabolic: Growth suppression, hyperuricemia, weight gain, weight loss</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Constipation (10%), gastrointestinal hemorrhage (2% to 9%; grades 3/4: 1% to 7%), abdominal distention, change in appetite, colitis (including neutropenic colitis), dysgeusia, dyspepsia, enterocolitis, gastritis, mucositis, stomatitis</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hematologic &amp; oncologic: Bruise</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hepatic: Increased serum bilirubin (grades 3/4: &le;6%), increased serum ALT (grades 3/4: &le;5%), increased serum AST (grades 3/4: &le;4%), ascites (&le;1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Infection: Herpes virus infection, sepsis</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Neuromuscular &amp; skeletal: Muscle spasm (5%), abnormal bone growth (children; epiphyses delayed fusion), stiffness, weakness</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Ophthalmic: Blurred vision, decreased visual acuity, dry eye syndrome, visual disturbance</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Otic: Tinnitus</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Renal: Increased serum creatinine (grades 3/4: &le;8%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Respiratory: Pulmonary hypertension (&le;5%; grades 3/4: &le;1%), pulmonary edema (&le;4%; grades 3/4: &le;3%), cough, pneumonia, pneumonitis, pulmonary infiltrates, upper respiratory tract infection</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Miscellaneous: Soft tissue injury (oral)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&lt;1%, postmarketing, and/or case reports: Abnormal gait, abnormal platelet aggregation, abnormal T waves on ECG, acute coronary syndrome, acute pancreatitis, acute respiratory distress, amnesia, anal fissure, angina pectoris, anxiety, arthritis, asthma, ataxia, atrial fibrillation, atrial flutter, bronchospasm, bullous skin disease, cardiomegaly, cerebrovascular accident, cholecystitis, cholestasis, confusion, conjunctivitis, coronary artery disease, cor pulmonale, cranial nerve palsy (facial), decreased libido, deep vein thrombosis, dehydration, dementia, dermal ulcer, diabetes mellitus, dyschromia, dysphagia, embolism, emotional lability, epistaxis, equilibrium disturbance, erythema nodosum, esophagitis, fibrosis (dermal), fistula (anal), gastroesophageal reflux disease, gastrointestinal disease (protein wasting), gingival hemorrhage, gynecomastia (adults and children), hearing loss, hematoma, hematuria, hemoptysis, hemorrhage (ocular), hepatitis, hypercholesterolemia, hypersensitivity reaction, hypersensitivity angiitis, hyperthyroidism, hypoalbuminemia, hypotension, hypothyroidism, increased creatine phosphokinase, increased gamma-glutamyl transferase, increased lacrimation, increased pulmonary artery pressure, increased troponin, inflammation (panniculitis), interstitial pulmonary disease, intestinal obstruction, livedo reticularis, lymphadenopathy, lymphocytopenia, malaise, menstrual disease, myocarditis, nail disease, nephrotic syndrome, optic neuritis, osteonecrosis, osteopenia (children), ototoxicity (hemorrhage), palmar-plantar erythrodysesthesia, pancreatitis, pericarditis, petechia, photophobia, pleuropericarditis, prolongation P-R interval on ECG, proteinuria, pulmonary embolism, pure red cell aplasia, reactivation of HBV, renal failure, renal insufficiency, rhabdomyolysis, seizure, skin photosensitivity, Stevens-Johnson syndrome, Sweet syndrome, syncope, tendonitis, thrombophlebitis, thrombosis, thyroiditis, transient ischemic attacks, tremor, tumor lysis syndrome, upper gastrointestinal tract ulcer, urinary frequency, uterine hemorrhage, vaginal hemorrhage, ventricular arrhythmia, ventricular tachycardia, vertigo, voice disorder</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F3020503\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">There are no contraindications listed in the manufacturer's US labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Canadian labeling:</i> Hypersensitivity to dasatinib or any other component of the formulation; breast-feeding</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F3020504\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Bone marrow suppression: Severe dose-related bone marrow suppression (thrombocytopenia, neutropenia, anemia) is associated with dasatinib treatment. Hematologic toxicity is usually reversible with dosage adjustment and/or temporary treatment interruption. The incidence of myelosuppression is higher in patients with advanced chronic myeloid leukemia (CML) and Ph+ acute lymphoblastic leukemia (ALL). Monitor blood counts every 2 weeks for 12 weeks and then every 3 months thereafter or as clinically indicated (for chronic phase CML) or weekly for the first 2 months, then monthly thereafter or as clinically necessary (for accelerated or blast phase CML or for ALL).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Cardiovascular adverse events: Dasatinib may cause cardiac dysfunction; cardiac ischemic events, cardiac fluid retention-related events, and conduction abnormalities (arrhythmia and palpitations) have been reported. Monitor for signs and symptoms of cardiac dysfunction. Monitor blood pressure routinely during dasatinib treatment; if indicated, initiate appropriate antihypertensive treatment to reduce the risk for cardiotoxicity (Armenian 2017).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Dermatologic toxicity: Cases of severe mucocutaneous dermatologic reactions (including Stevens-Johnson syndrome and erythema multiforme) have been reported with dasatinib. Discontinue dasatinib if severe mucocutaneous reaction occurs and other etiologies have been ruled out.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Fluid retention: Dasatinib may cause fluid retention, including pleural and pericardial effusions, pulmonary hypertension, and generalized or superficial edema. A prompt chest x-ray (or other appropriate diagnostic imaging) is recommended for symptoms suggestive of effusion (new or worsening dyspnea on exertion or at rest, pleuritic chest pain, or dry cough). Fluid retention may be managed with supportive care (diuretics or corticosteroids); thoracentesis and oxygen therapy may be necessary for severe fluid retention; consider dose reduction or treatment interruption. Utilizing once-daily dosing is associated with a decreased frequency of fluid retention. The risk for pleural effusion is increased in patients with hypertension, prior cardiac history and a twice a day administration schedule; interrupt treatment for grade &ge;2 effusion; may consider reinitiating at a reduced dose after resolution (Quint&aacute;s-Cardama 2007). Grade 3 or 4 fluid retention/pleural effusion was observed in adults and grade 1 or 2 fluid retention was observed in pediatric patients. Use with caution in patients where fluid accumulation may be poorly tolerated, such as in cardiovascular disease (HF or hypertension) and pulmonary disease.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hemorrhage: Dasatinib may cause serious and fatal bleeding, including grades 3 and higher CNS hemorrhage. The most frequent hemorrhage site was gastrointestinal. Grades 3 or 4 hemorrhage usually required treatment interruptions and transfusions. Most bleeding events in clinical studies were associated with severe thrombocytopenia, although dasatinib may also cause platelet dysfunction. Concomitant medications that inhibit platelet function or anticoagulants may increase the risk of bleeding.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Pulmonary arterial hypertension: Dasatinib may increase the risk for pulmonary arterial hypertension (PAH) in both adult and pediatric patients. PAH may occur at any time after starting treatment, including after &gt;12 months of therapy. Evaluate for underlying cardiopulmonary disease prior to therapy initiation and during therapy; evaluate and rule out alternative etiologies in patients with symptoms suggestive of PAH (eg, dyspnea, fatigue, hypoxia, fluid retention) and interrupt therapy if symptoms are severe. Discontinue permanently with confirmed PAH diagnosis (may be reversible upon discontinuation).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; QT prolongation: Dasatinib may increase the risk for QT interval prolongation; there are reports of patients with QTcF &gt;500 msec. Use caution in patients at risk for QT prolongation, including patients with long QT syndrome, patients taking antiarrhythmic medications or other medications that lead to QT prolongation or potassium-wasting diuretics, patients with cumulative high-dose anthracycline therapy, and conditions which cause hypokalemia or hypomagnesemia. Correct hypokalemia and hypomagnesemia prior to and during dasatinib therapy.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Tumor lysis syndrome: Tumor lysis syndrome (TLS) has been reported in patients with resistance to imatinib therapy, usually in patients with advanced phase disease. Risk for TLS is higher in patients with advanced stage disease and/or a high tumor burden; monitor patients at risk more frequently. Maintain adequate hydration and correct uric acid levels prior to treatment; monitor electrolyte levels.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hepatic impairment: Use with caution in patients with hepatic impairment due to extensive hepatic metabolism.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information. Use with caution in patients taking anticoagulants or medications interfering with platelet function; not studied in clinical trials. Avoid concomitant use with CYP3A4 inducers and inhibitors; if concomitant use cannot be avoided, consider dasatinib dosage adjustments.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drugs that affect gastric pH: Elevated gastric pH may reduce dasatinib bioavailability; do not administer proton pump inhibitors and H<sub>2</sub> blockers concomitantly with dasatinib. If needed, may consider antacid administration separated by at least 2 hours before or 2 hours after the dasatinib dose.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Elderly: Patients 65 years of age and older are more likely to experience toxicity (compared with younger patients).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Pediatrics: Adverse reactions associated with bone growth and development have been reported in pediatric studies of chronic phase CML (including a report of severe [grade 3] growth retardation). Cases have included epiphyses delayed fusion, osteopenia, growth retardation, and gynecomastia; some cases resolved during treatment. Monitor bone growth/development in pediatric patients.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F3020515\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Substrate</b> of CYP3A4 (major); <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential; <b>Inhibits</b> CYP3A4 (weak)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F3020514\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=8852&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Acetaminophen: May enhance the hepatotoxic effect of Dasatinib. Dasatinib may increase the serum concentration of Acetaminophen.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Agents with Antiplatelet Properties (e.g., P2Y12 inhibitors, NSAIDs, SSRIs, etc.): Dasatinib may enhance the anticoagulant effect of Agents with Antiplatelet Properties. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Antacids: May decrease the absorption of Dasatinib.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Anticoagulants: Dasatinib may enhance the anticoagulant effect of Anticoagulants. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Aprepitant: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">ARIPiprazole: CYP3A4 Inhibitors (Weak) may increase the serum concentration of ARIPiprazole.  Management: Monitor for increased aripiprazole pharmacologic effects. Aripiprazole dose adjustments may or may not be required based on concomitant therapy and/or indication. Consult full interaction monograph for specific recommendations.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">BCG (Intravesical): Immunosuppressants may diminish the therapeutic effect of BCG (Intravesical). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">BCG (Intravesical): Myelosuppressive Agents may diminish the therapeutic effect of BCG (Intravesical). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bosentan: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ceritinib: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors). Management: Use of ceritinib with a narrow therapeutic index CYP3A substrate (eg, alfentanil, cyclosporine, dihydroergotamine, ergotamine, fentanyl, pimozide, quinidine, sirolimus, tacrolimus) should be avoided when possible.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Chloramphenicol (Ophthalmic): May enhance the adverse/toxic effect of Myelosuppressive Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CloZAPine: Myelosuppressive Agents may enhance the adverse/toxic effect of CloZAPine. Specifically, the risk for neutropenia may be increased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Coccidioides immitis Skin Test: Immunosuppressants may diminish the diagnostic effect of Coccidioides immitis Skin Test. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Conivaptan: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP3A4 Inducers (Moderate): May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP3A4 Inducers (Strong): May decrease the serum concentration of Dasatinib. Management: Avoid when possible. If such a combination cannot be avoided, consider increasing dasatinib dose and monitor clinical response and toxicity closely.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP3A4 Inhibitors (Moderate): May decrease the metabolism of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP3A4 Inhibitors (Strong): May increase the serum concentration of Dasatinib. Management: This combination should be avoided; consider reducing dasatinib dose if a strong CYP3A4 inhibitor must be used. If using dasatinib 70 mg/day or 100 mg/day, consider reduction to 20 mg/day; if using dasatinib 140 mg/day, consider reduction to 40 mg/day.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP3A4 Substrates (High risk with Inhibitors): Dasatinib may increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dabrafenib: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers). Management: Seek alternatives to the CYP3A4 substrate when possible.  If concomitant therapy cannot be avoided, monitor clinical effects of the substrate closely (particularly therapeutic effects).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Deferasirox: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Deferiprone: Myelosuppressive Agents may enhance the neutropenic effect of Deferiprone. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Denosumab: May enhance the adverse/toxic effect of Immunosuppressants. Specifically, the risk for serious infections may be increased.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dexamethasone (Systemic): May decrease the serum concentration of Dasatinib. Management: Avoid when possible. If such a combination cannot be avoided, consider increasing dasatinib dose and monitoring clinical response and toxicity closely.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dipyrone: May enhance the adverse/toxic effect of Myelosuppressive Agents. Specifically, the risk for agranulocytosis and pancytopenia may be increased<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Echinacea: May diminish the therapeutic effect of Immunosuppressants.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Enzalutamide: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers). Management: Concurrent use of enzalutamide with CYP3A4 substrates that have a narrow therapeutic index should be avoided.  Use of enzalutamide and any other CYP3A4 substrate should be performed with caution and close monitoring.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fingolimod: Immunosuppressants may enhance the immunosuppressive effect of Fingolimod.  Management: Avoid the concomitant use of fingolimod and other immunosuppressants when possible. If combined, monitor patients closely for additive immunosuppressant effects (eg, infections).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Flibanserin: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Flibanserin. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fosaprepitant: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fusidic Acid (Systemic): May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Grapefruit Juice: May increase the serum concentration of Dasatinib.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Histamine H2 Receptor Antagonists: May decrease the absorption of Dasatinib. Management: Antacids (taken 2 hours before or after dasatinib administration) can be used in place of H2-antagonists if some acid-reducing therapy is needed.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Idelalisib: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Leflunomide: Immunosuppressants may enhance the adverse/toxic effect of Leflunomide. Specifically, the risk for hematologic toxicity such as pancytopenia, agranulocytosis, and/or thrombocytopenia may be increased.  Management: Consider not using a leflunomide loading dose in patients receiving other immunosuppressants.  Patients receiving both leflunomide and another immunosuppressant should be monitored for bone marrow suppression at least monthly.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lomitapide: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Lomitapide.  Management: Patients on lomitapide 5 mg/day may continue that dose. Patients taking lomitapide 10 mg/day or more should decrease the lomitapide dose by half. The lomitapide dose may then be titrated up to a max adult dose of 30 mg/day.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">MiFEPRIStone: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors). Management: Minimize doses of CYP3A4 substrates, and monitor for increased concentrations/toxicity, during and 2 weeks following treatment with mifepristone. Avoid cyclosporine, dihydroergotamine, ergotamine, fentanyl, pimozide, quinidine, sirolimus, and tacrolimus.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">MiFEPRIStone: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying). Management: Though the drugs listed here have uncertain QT-prolonging effects, they all have some possible association with QT prolongation and should generally be avoided when possible.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mitotane: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers). Management: Doses of CYP3A4 substrates may need to be adjusted substantially when used in patients being treated with mitotane.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Natalizumab: Immunosuppressants may enhance the adverse/toxic effect of Natalizumab. Specifically, the risk of concurrent infection may be increased. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Netupitant: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">NiMODipine: CYP3A4 Inhibitors (Weak) may increase the serum concentration of NiMODipine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nivolumab: Immunosuppressants may diminish the therapeutic effect of Nivolumab. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ocrelizumab: May enhance the immunosuppressive effect of Immunosuppressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Palbociclib: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pidotimod: Immunosuppressants may diminish the therapeutic effect of Pidotimod. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pimecrolimus: May enhance the adverse/toxic effect of Immunosuppressants.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pimozide: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Pimozide. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pitolisant: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers). Management: Combined use of pitolisant with a CYP3A4 substrate that has a narrow therapeutic index should be avoided. Other CYP3A4 substrates should be monitored more closely when used with pitolisant.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Promazine: May enhance the myelosuppressive effect of Myelosuppressive Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Propacetamol: Dasatinib may enhance the hepatotoxic effect of Propacetamol. Dasatinib may increase serum concentrations of the active metabolite(s) of Propacetamol. Specifically, acetaminophen concentrations may increase. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Proton Pump Inhibitors: May decrease the serum concentration of Dasatinib. Management: Antacids (taken 2 hours before or after dasatinib administration) can be used in place of the proton pump inhibitor if some acid-reducing therapy is needed.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">QTc-Prolonging Agents (Highest Risk): QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying) may enhance the QTc-prolonging effect of QTc-Prolonging Agents (Highest Risk).  Management: Avoid such combinations when possible.  Use should be accompanied by close monitoring for evidence of QT prolongation or other alterations of cardiac rhythm.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">QTc-Prolonging Agents (Moderate Risk): QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying) may enhance the QTc-prolonging effect of QTc-Prolonging Agents (Moderate Risk). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Roflumilast: May enhance the immunosuppressive effect of Immunosuppressants.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sarilumab: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Siltuximab: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Simeprevir: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sipuleucel-T: Immunosuppressants may diminish the therapeutic effect of Sipuleucel-T. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">St John's Wort: May decrease the serum concentration of Dasatinib.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Stiripentol: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors). Management: Use of stiripentol with CYP3A4 substrates that are considered to have a narrow therapeutic index should be avoided due to the increased risk for adverse effects and toxicity.  Any CYP3A4 substrate used with stiripentol requires closer monitoring.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tacrolimus (Topical): May enhance the adverse/toxic effect of Immunosuppressants.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tertomotide: Immunosuppressants may diminish the therapeutic effect of Tertomotide. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tocilizumab: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tofacitinib: Immunosuppressants may enhance the immunosuppressive effect of Tofacitinib.  Management: Concurrent use with antirheumatic doses of methotrexate or nonbiologic disease modifying antirheumatic drugs (DMARDs) is permitted, and this warning seems particularly focused on more potent immunosuppressants.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Trastuzumab: May enhance the neutropenic effect of Immunosuppressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vaccines (Inactivated): Immunosuppressants may diminish the therapeutic effect of Vaccines (Inactivated).  Management: Vaccine efficacy may be reduced. Complete all age-appropriate vaccinations at least 2 weeks prior to starting an immunosuppressant. If vaccinated during immunosuppressant therapy, revaccinate at least 3 months after immunosuppressant discontinuation.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vaccines (Live): Immunosuppressants may enhance the adverse/toxic effect of Vaccines (Live). Immunosuppressants may diminish the therapeutic effect of Vaccines (Live).  Management: Avoid use of live organism vaccines with immunosuppressants; live-attenuated vaccines should not be given for at least 3 months after immunosuppressants.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Voriconazole: May enhance the QTc-prolonging effect of Dasatinib. Voriconazole may increase the serum concentration of Dasatinib. Management: This combination should be avoided; consider reducing dasatinib dose if voriconazole must be used. If using dasatinib 100 mg/day, consider reduction to 20 mg/day; if using dasatinib 140 mg/day, consider reduction to 40 mg/day.  Monitor ECG closely.<i> Risk D: Consider therapy modification</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F3020518\" class=\"block foi drugH1Div\"><span class=\"drugH1\">Food Interactions</span>\n    <p style=\"text-indent:0em;display:inline\">Dasatinib serum concentrations may be increased when taken with grapefruit or grapefruit juice. Management: Avoid concurrent use.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5520659\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Dasatinib crosses the placenta, with fetal plasma and amniotic concentrations comparable to maternal concentrations. Adverse effects, including hydrops fetalis and fetal leukopenia and thrombocytopenia have been reported following maternal exposure to dasatinib. Women of reproductive potential should use effective contraception during treatment and for 30 days after the final dasatinib dose. Pregnant women are advised to avoid exposure to crushed or broken tablets.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6743584\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">It is not known if dasatinib is present in breast milk. Due to the potential for serious adverse reactions in the breastfed infant, breastfeeding is not recommended by the manufacturer during treatment and for 2 weeks following the final dose.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F3020535\" class=\"block dic drugH1Div\"><span class=\"drugH1\">Dietary Considerations</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Avoid grapefruit juice.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F3020538\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">CBC with differential every 2 weeks for 12 weeks and then every 3 months thereafter or as clinically indicated (for chronic phase chronic myeloid leukemia [CML]) <b>or</b> weekly for 2 months, then monthly or as clinically necessary (for accelerated or blast phase CML or for acute lymphoblastic leukemia [ALL]); bone marrow biopsy; liver function tests, electrolytes including calcium, phosphorus, magnesium; monitor for fluid retention; monitor for signs/symptoms of cardiac dysfunction; ECG monitoring if at risk for QT<sub>c</sub> prolongation; chest x-ray is recommended for symptoms suggestive of pleural effusion (eg, cough, dyspnea); signs/symptoms of tumor lysis syndrome and dermatologic reactions. Monitor bone growth/development in pediatric patients. Monitor blood pressure routinely (Armenian 2017). Monitor adherence.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">Thyroid function testing recommendations (Hamnvik 2011):</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Preexisting levothyroxine therapy: Obtain baseline TSH levels, then monitor every 4 weeks until levels and levothyroxine dose are stable, then monitor every 2 months</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Without preexisting thyroid hormone replacement: TSH at baseline, then monthly for 4 months, then every 2 to 3 months</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F3020521\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Dasatinib is a BCR-ABL tyrosine kinase inhibitor that targets most imatinib-resistant BCR-ABL mutations (except the T315I and F317V mutants) by distinctly binding to active and inactive ABL-kinase. Kinase inhibition halts proliferation of leukemia cells. It also inhibits SRC family (including SRC, LKC, YES, FYN); c-KIT, EPHA2 and platelet derived growth factor receptor (PDGFR&beta;).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F3020523\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Distribution: 2,505 L</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Protein binding: Dasatinib: ~96%; metabolite (active): 93%</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bioavailability: Exposure is lower in patients receiving a crushed tablet (compared with an intact tablet).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Metabolism: Hepatic (extensive); metabolized by CYP3A4 (primarily), flavin-containing mono-oxygenase-3 (FOM-3) and uridine diphosphate-glucuronosyltransferase (UGT) to an active metabolite and other inactive metabolites (the active metabolite plays only a minor role in the pharmacology of dasatinib)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Half-life elimination: Terminal: 3 to 5 hours (adults); 2 to 5 hours (pediatrics)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Time to peak, plasma: 0.5 to 6 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Excretion: Feces (~85%, 19% as unchanged drug); urine (~4%, 0.1% as unchanged drug)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16322945\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Sprycel Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">20 mg (60): $8,596.92</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">50 mg (60): $17,193.82</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">70 mg (60): $17,193.82</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">80 mg (30): $15,494.48</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">100 mg (30): $15,494.48</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">140 mg (30): $15,494.48</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5539976\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Dasanix (BD);</li>\n      <li>Etersa (EC);</li>\n      <li>Liteda (EC);</li>\n      <li>Rembre (EC);</li>\n      <li>Sprycel (AE, AR, AT, AU, BB, BE, BG, BH, BR, CH, CL, CN, CO, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HK, HN, HR, HU, ID, IE, IL, IN, IS, IT, JO, JP, KR, KW, LB, LT, LU, LV, MT, MY, NL, NO, NZ, PE, PL, PT, QA, RO, RU, SA, SE, SG, SI, SK, TH, TR, TW, UY)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Apperley JF, Cortes JE, Kim DW, et al, &ldquo;Dasatinib in the Treatment of Chronic Myeloid Leukemia in Accelerated Phase After Imatinib Failure: The START A Trial,&rdquo; <i>J Clin Oncol</i>, 2009, 27(21):3472-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dasatinib-drug-information/abstract-text/19487385/pubmed\" target=\"_blank\" id=\"19487385\">19487385</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Armenian SH, Lacchetti C, Barac A, et al. Prevention and monitoring of cardiac dysfunction in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline. <i>J Clin Oncol</i>. 2017;35(8):893-911.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dasatinib-drug-information/abstract-text/27918725/pubmed\" target=\"_blank\" id=\"27918725\">27918725</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Assouline S, Laneuville P and Gambacorti-Passerini C, &ldquo;Panniculitis During Dasatinib Therapy for Imatinib-Resistant Chronic Myelogenous Leukemia,&rdquo; <i>N Engl J Med</i>, 2006, 354(24):2623-4.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dasatinib-drug-information/abstract-text/16775249/pubmed\" target=\"_blank\" id=\"16775249\">16775249</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Berveiller P, Andreoli A, Mir O, et al, &ldquo;A Dramatic Fetal Outcome Following Transplacental Transfer of Dasatinib,&rdquo; <i>Anticancer Drugs</i>, 2012, 23(7):754-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dasatinib-drug-information/abstract-text/22421368/pubmed\" target=\"_blank\" id=\"22421368\">22421368</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bradeen HA, Eide CA, O'Hare T, et al, &ldquo;Comparison of Imatinib, Dasatinib (BMS-354825), and Nilotinib (AMN107) in an N-Ethyl-N-Nitrosourea (ENU)-Based Mutagenesis Screen: High Efficacy of Drug Combinations,&rdquo; <i>Blood</i>, 2006, 108(7):2332-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dasatinib-drug-information/abstract-text/16772610/pubmed\" target=\"_blank\" id=\"16772610\">16772610</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Copland M, Hamilton A, Elrick LJ, et al, &ldquo;Dasatinib (BMS-354825) Targets an Earlier Progenitor Population Than Imatinib in Primary CML But Does Not Eliminate the Quiescent Fraction,&rdquo; <i> Blood</i>, 2006, 107(11):4532-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dasatinib-drug-information/abstract-text/16469872/pubmed\" target=\"_blank\" id=\"16469872\">16469872</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Cornelison M, Jabbour EJ, and Welch MA, &ldquo;Managing Side Effects of Tyrosine Kinase Inhibitor Therapy to Optimize Adherence in Patients With Chronic Myeloid Leukemia: The Role of the Midlevel Practitioner,&rdquo; <i>J Support Oncol</i>, 2012, 10(1):14-24.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dasatinib-drug-information/abstract-text/22244674/pubmed\" target=\"_blank\" id=\"22244674\">22244674</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Cortes J, Rousselot P, Kim DW, et al, &ldquo;Dasatinib Induces Complete Hematologic and Cytogenetic Responses in Patients With Imatinib-Resistant or Intolerant Chronic Myeloid Leukemia in Blast Crisis,&rdquo; <i>Blood</i>, 2007, 109(8):3207-13.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dasatinib-drug-information/abstract-text/17185463/pubmed\" target=\"_blank\" id=\"17185463\">17185463</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Guilhot F, Apperley J, Kim DW, et al, &ldquo;Dasatinib Induces Significant Hematologic and Cytogenetic Responses in Patients With Imatinib-Resistant or Intolerant Chronic Myeloid Leukemia in Accelerated Phase,&rdquo; <i>Blood</i>, 2007, 109(10):4143-50.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dasatinib-drug-information/abstract-text/17264298/pubmed\" target=\"_blank\" id=\"17264298\">17264298</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hamnvik OP, Larsen PR, and Marqusee E, &ldquo;Thyroid Dysfunction From Antineoplastic Agents,&rdquo; <i>J Natl Cancer Inst</i>, 2011, 103(21):1572-87.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dasatinib-drug-information/abstract-text/22010182/pubmed\" target=\"_blank\" id=\"22010182\">22010182</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hochhaus A, Kantarjian HM, Baccarani M, et al, &ldquo;Dasatinib Induces Notable Hematologic and Cytogenetic Responses in Chronic-Phase Chronic Myeloid Leukemia After Failure of Imatinib Therapy,&rdquo; <i>Blood</i>, 2007, 109(6):2303-09.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dasatinib-drug-information/abstract-text/17138817/pubmed\" target=\"_blank\" id=\"17138817\">17138817</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kantarjian H, Cortes J, Kim DW, et al, &quot;Phase 3 Study of Dasatinib 140 mg Once Daily versus 70 mg Twice Daily in Patients With Chronic Myeloid Leukemia in Accelerated Phase Resistant or Intolerant to Imatinib: 15-Month Median Follow-up,&quot; <i>Blood</i>, 2009, 113(25):6322-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dasatinib-drug-information/abstract-text/19369231/pubmed\" target=\"_blank\" id=\"19369231\">19369231</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kantarjian HM, Shah NP, Cortes JE, et al, &ldquo;Dasatinib or Imatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia: 2-year Follow-up From a Randomized Phase 3 Trial (DASISION),&rdquo; <i>Blood</i>, 2012, 119(5):1123-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dasatinib-drug-information/abstract-text/22160483/pubmed\" target=\"_blank\" id=\"22160483\">22160483</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kantarjian H, Shah NP, Hochhaus A, et al, &ldquo;Dasatinib Versus Imatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia,&rdquo; <i>N Engl J Med</i>, 2010, 362(24):2260-70.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dasatinib-drug-information/abstract-text/20525995/pubmed\" target=\"_blank\" id=\"20525995\">20525995</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Khoury HJ, Guilhot F, Hughes TP, et al. Dasatinib treatment for Philadelphia chromosome-positive leukemias: practical considerations. <i>Cancer</i>. 2009;115(7):1381-1394.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dasatinib-drug-information/abstract-text/19195046/pubmed\" target=\"_blank\" id=\"19195046\">19195046</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lilly MB, Ottmann OG, Shah NP, et al, &ldquo;Dasatinib 140 mg Once Daily versus 70 mg Twice Daily in Patients With Ph-Positive Acute Lymphoblastic Leukemia Who Failed Imatinib: Results From a Phase 3 Study,&rdquo; <i>Am J Hematol</i>, 2010, 85(3):164-70.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dasatinib-drug-information/abstract-text/20131302/pubmed\" target=\"_blank\" id=\"20131302\">20131302</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"Montemurro.2012\"></a>Montemurro M, Domont J, Blesius A, et al, &ldquo;Dasatinib First-Line Treatment in Gastrointestinal Stromal Tumors: A Multicenter Phase II Trial of the SAKK (SAKK 56/07),&rdquo; <i>J Clin Oncol</i>, 2012, 30(15s):10033 [abstract 10033 from 2012 ASCO Annual Meeting].</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ottmann O, Dombret H, Martinelli G, et al, &ldquo;Dasatinib Induces Rapid Hematologic and Cytogenetic Responses in Adult Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia With Intolerance to Imatinib: Interim Results of a Phase 2 Study,&rdquo; <i>Blood</i>, 2007, 110(7):2309-15.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dasatinib-drug-information/abstract-text/17496201/pubmed\" target=\"_blank\" id=\"17496201\">17496201</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Quintas-Cardama A, Han X, Kantarjian H, et al, &ldquo;Dasatinib-Induced Platelet Dysfunction,&rdquo; <i>Blood</i> 2007, 110:2941 [abstract 2941 from 2007 ASH Annual Meeting].</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Quint&aacute;s-Cardama A, Kantarjian H, O'brien S, et al, &ldquo;Pleural Effusion in Patients With Chronic Myelogenous Leukemia Treated With Dasatinib After Imatinib Failure,&rdquo; <i>J Clin Oncol</i>, 2007, 25(25):3908-14.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dasatinib-drug-information/abstract-text/17761974/pubmed\" target=\"_blank\" id=\"17761974\">17761974</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Saglio G, Hochhaus A, Goh YT, et al, &quot;Dasatinib in Imatinib-Resistant or Imatinib-Intolerant Chronic Myeloid Leukemia in Blast Phase After 2 Years of Follow-up in a Phase 3 Study: Efficacy and Tolerability of 140 Milligrams Once Daily and 70 Milligrams Twice Daily,&quot; <i>Cancer</i>, 2010, 116(16):3852-61.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dasatinib-drug-information/abstract-text/20564086/pubmed\" target=\"_blank\" id=\"20564086\">20564086</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Shah NP, Guilhot F, Cortes JE, et al. Long-term outcome with dasatinib after imatinib failure in chronic-phase chronic myeloid leukemia: follow-up of a phase 3 study. <i>Blood</i>. 2014;123(15):2317-2324.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dasatinib-drug-information/abstract-text/24569263/pubmed\" target=\"_blank\" id=\"24569263\">24569263</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Shah NP, Kantarjian HM, Kim DW, et al, &ldquo;Intermittent Target Inhibition With Dasatinib 100 mg Once Daily Preserves Efficacy and Improves Tolerability in Imatinib-Resistant and -Intolerant Chronic-Phase Chronic Myeloid Leukemia,&rdquo; <i>J Clin Oncol</i>, 2008, 26(19):3204-12.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dasatinib-drug-information/abstract-text/18541900/pubmed\" target=\"_blank\" id=\"18541900\">18541900</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Shah NP, Kim DW, Kantarjian H, et al, &ldquo;Potent, Transient Inhibition of BCR-ABL With Dasatinib 100 mg Daily Achieves Rapid and Durable Cytogenetic Responses and High Transformation-Free Survival Rates in Chronic Phase Chronic Myeloid Leukemia Patients With Resistance, Suboptimal Response or Intolerance to Imatinib,&rdquo; <i>Haematologica</i>, 2010, 95(2):232-40.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dasatinib-drug-information/abstract-text/20139391/pubmed\" target=\"_blank\" id=\"20139391\">20139391</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Sprycel (dasatinib) [prescribing information]. Princeton, NJ: Bristol-Myers Squibb Company; November 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Sprycel (dasatinib) [product monograph]. Montreal, Canada: Bristol-Myers Squibb Canada; July 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Talpaz M, Shah NP, Kantarjian H, et al, &ldquo;Dasatinib in Imatinib-Resistant Philadelphia Chromosome-Positive Leukemias,&rdquo; <i>N Engl J Med</i>, 2006, 354(24):2531-41.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dasatinib-drug-information/abstract-text/16775234/pubmed\" target=\"_blank\" id=\"16775234\">16775234</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"Trent.2011\"></a>Trent JC, Wathen J, von Mehren M, et al, &ldquo;A Phase II Study of Dasatinib for Patients With Imatinib-Resistant Gastrointestinal Stromal Tumor (GIST),&rdquo; <i>J Clin Oncol</i>, 2011, 29(15s):10006 [abstract 10006 from 2011 ASCO Annual Meeting].</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    US Department of Health and Human Services; Centers for Disease Control and Prevention; National Institute for Occupational Safety and Health. NIOSH list of antineoplastic and other hazardous drugs in healthcare settings 2016. <a href=\"http://www.cdc.gov/niosh/topics/antineoplastic/pdf/hazardous-drugs-list_2016-161.pdf\" target=\"_blank\">http://www.cdc.gov/niosh/topics/antineoplastic/pdf/hazardous-drugs-list_2016-161.pdf</a>. Updated September 2016. Accessed October 5, 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Zwaan CM, Rizzari C, Mechinaud F, et al. Dasatinib in children and adolescents with relapsed or refractory leukemia: results of the CA180-018 phase I dose-escalation study of the Innovative Therapies for Children with Cancer Consortium. <i>J Clin Oncol</i>. 2013;31(19):2460-2468.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dasatinib-drug-information/abstract-text/23715577/pubmed\" target=\"_blank\" id=\"23715577\">23715577</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 8852 Version 182.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F3020472\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F4663157\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F3020476\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F3020532\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Pediatric\" href=\"#F50836850\" class=\"outlineLink\">Dosing: Pediatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F3020533\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F15121210\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F7882679\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adjustment for Toxicity\" href=\"#F3020534\" class=\"outlineLink\">Dosing: Adjustment for Toxicity</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F3020543\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F3020474\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F3020536\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Hazardous Drugs Handling Considerations\" href=\"#F49130978\" class=\"outlineLink\">Hazardous Drugs Handling Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F3020479\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Use: Off-Label\" href=\"#F25475178\" class=\"outlineLink\">Use: Off-Label</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F3401602\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F3020507\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F3020503\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F3020504\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F3020515\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F3020514\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Food Interactions\" href=\"#F3020518\" class=\"outlineLink\">Food Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F5520659\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F6743584\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Dietary Considerations\" href=\"#F3020535\" class=\"outlineLink\">Dietary Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F3020538\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F3020521\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F3020523\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F16322945\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F5539976\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/8852|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=dasatinib-patient-drug-information\" class=\"drug drug_patient\">Dasatinib: Patient drug information</a></li></ul></div></div>","javascript":null}